Objective: To assess the long-term results of the introduction of autologous mesenchymal stem cells (MSCs)  on the intensity of motor and non-motor symptoms and on the concentration of interleukin-10 in blood serum in patients with Parkinson’s disease (PD).

Background: The pathogenesis of PD is based on the mutual reinforcement of neurodegeneration and neuroinflammation.The search for treatment that allows us to regulate these processes is a priority task of modern research. The use of MSCs from bone marrow is considered as a therapy capable of modifying the course of PD. The most important role in the efficacy of this kind of therapy plays paracrine activity of MSCs.

Method: MSCs were injected to 23 patients with PD via systemic and tandem (intranasal + intravenous) methods. 13 patients with PD were administered 0.9% saline solution (placebo). The intensity of motor and non-motor symptoms of PD, the concentration of interleukin-10 in the blood serum was evaluated 1, 3, 6, 9 and 12 months after the first injection. The severity of motor symptoms was assessed with the help of Section III of the MDS-Unified Parkinson’s Disease Rating Scale (UPDRS).The intensity of non-motor symptoms was assessed with the help of the following scales: Hamilton Depression Rating Scale (HDRS), Non-Motor Symptoms Scale (NMSS).

Results: A statistically significant decrease in the severity of motor and non-motor symptoms of PD was noted in the patients 1, 3, 6 months after the use of MSCs and no statistically significant changes were found  9 and 12 months after the MSCs injection, the levels of interleukin-10 temporarily increased for those patients, who had the most significant clinical improvement.

In the placebo group, statistically significant increase of the motor symptoms was observed 3, 6, 9, 12  months after the placebo administration in the off-period and after 6 , 9, 12 months in the on-period, as well as statistically significant decrease of interleukin-10 level after 12 months.

Conclusion: A long-term positive effect of MSCs on the dynamics of symptoms of PD consisted of an improvement in motor function and a decrease in the severity of non-motor symptoms lasting, on average, 6 months and the absence of clinical signs of the disease progression after 12 months from the first administration of MSCs. The results indicate the correlation between the dynamics of motor symptoms of PD and the concentration of interleukin-10 in the blood serum.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/modification-of-parkinsons-disease-%d1%81ourse-using-cell-technologies/